WATERTOWN, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals, the leader in the discovery and development of novel gene control therapies for cancer and other serious diseases, announced today that management will participate in two investor conferences during the month of September:
- 22nd Annual NewsMakers in the Biotech Industry Conference, Thursday, September 10, 2015; Millennium Broadway Hotel, New York City. Management will present a corporate overview at 11:30 a.m. ET.
- 2015 Morgan Stanley Global Healthcare Conference, Friday, September 18, 2015; Grand Hyatt Hotel, New York City.
About Syros Pharmaceuticals
Syros Pharmaceuticals is a therapeutics company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics and biomarkers. The Company’s founders are pioneers in gene control research and translation. Co-founded by Flagship Ventures and ARCH Venture Partners, Syros Pharmaceuticals is located in Watertown, Mass. For more information, visit www.syros.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150908005876/en/
Media Contact:
Ten Bridge Communications, Inc.
Dan
Quinn, 781-475-7974
dan@tenbridgecommunications.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Jesse Baumgartner,
212-362-1200
jesse@sternir.com
Source: Syros Pharmaceuticals
Released September 8, 2015